These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 12718934)
1. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Tanaka H; Shimizu K; Hayashi T; Shu S Cell Immunol; 2002 Nov; 220(1):1-12. PubMed ID: 12718934 [TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. Cho EI; Tan C; Koski GK; Cohen PA; Shu S; Lee WT Head Neck; 2010 Jun; 32(6):700-7. PubMed ID: 19908319 [TBL] [Abstract][Full Text] [Related]
3. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424 [TBL] [Abstract][Full Text] [Related]
4. [Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations]. Shimizu K; Kuriyama H; Tamai H; Ueda Y; Yamagishi H; Shu S Gan To Kagaku Ryoho; 2004 Oct; 31(11):1637-9. PubMed ID: 15553668 [TBL] [Abstract][Full Text] [Related]
5. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387 [TBL] [Abstract][Full Text] [Related]
7. Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Lee WT; Shimizu K; Kuriyama H; Tanaka H; Kjaergaard J; Shu S Otolaryngol Head Neck Surg; 2005 May; 132(5):755-64. PubMed ID: 15886631 [TBL] [Abstract][Full Text] [Related]
8. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Kuriyama H; Shimizu K; Lee W; Kjaergaard J; Parkhurst MR; Cohen PA; Shu S Dev Biol (Basel); 2004; 116():169-78; discussion 179-86. PubMed ID: 15603192 [TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Hayashi T; Tanaka H; Tanaka J; Wang R; Averbook BJ; Cohen PA; Shu S Clin Immunol; 2002 Jul; 104(1):14-20. PubMed ID: 12139943 [TBL] [Abstract][Full Text] [Related]
12. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685 [TBL] [Abstract][Full Text] [Related]
13. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815 [TBL] [Abstract][Full Text] [Related]
14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
15. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033 [TBL] [Abstract][Full Text] [Related]
16. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity. Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786 [TBL] [Abstract][Full Text] [Related]
17. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour. Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440 [TBL] [Abstract][Full Text] [Related]
18. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528 [TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]